New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Unitaid Calls For Proposals To Develop Technologies To Treat Malaria, HIV, TB 13/02/2019 David Branigan Unitaid has launched two separate calls for proposals for the development of improved technologies to better diagnose and treat Plasmodium vivax malaria, and to more effectively treat HIV and its coinfections, including tuberculosis and malaria, in low and middle-income countries. Continue reading -> Ending TB: Multi-Sectoral Collaboration Needed To Tackle Disease Of Poverty, Board Says 01/02/2019 Editorial team There is a need to strengthen multisectoral collaboration to halt the global tuberculosis epidemic, WHO Executive Board (EB) members said in a review of the WHO End TB Strategy, which aims to reduce TB deaths by 90 percent by 2030. Continue reading -> DNDi, MMV Make 400 Compounds Available To Boost Pandemic Disease Research 29/01/2019 William New The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) today announced the launch of the "Pandemic Response Box", which offers researchers free access to 400 compounds that could lead to development of new treatments for pandemic diseases. In return, researchers "will be expected to share data resulting from research on the molecules from the box in the public domain within 2 years of its generation." Continue reading -> G-Finder: R&D Investments Reach 10-Year Peak 23/01/2019 Health Policy Watch Funding for neglected disease research and development reached its highest level in a decade, with US $3.56 billion in investments in 2017. Continue reading -> Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Video: Stopping Malaria Relapse – New Approaches For An Old Disease 22/01/2019 Editorial team Medicines for Malaria Venture (MMV) tells the story of the new single-dose tefanoquine treatment for relapsing malaria, caused by the Plasmodium vivax species of the parasite – the most widespread in the world. Continue reading -> Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> Enter The African Medicines Agency, Continent’s First Super-Regulator? 03/07/2017 Tatum Anderson An African medicines agency, the continent’s first super-regulator, could be approved as soon as next year. Continue reading -> Posts navigation Newer posts
Unitaid Calls For Proposals To Develop Technologies To Treat Malaria, HIV, TB 13/02/2019 David Branigan Unitaid has launched two separate calls for proposals for the development of improved technologies to better diagnose and treat Plasmodium vivax malaria, and to more effectively treat HIV and its coinfections, including tuberculosis and malaria, in low and middle-income countries. Continue reading -> Ending TB: Multi-Sectoral Collaboration Needed To Tackle Disease Of Poverty, Board Says 01/02/2019 Editorial team There is a need to strengthen multisectoral collaboration to halt the global tuberculosis epidemic, WHO Executive Board (EB) members said in a review of the WHO End TB Strategy, which aims to reduce TB deaths by 90 percent by 2030. Continue reading -> DNDi, MMV Make 400 Compounds Available To Boost Pandemic Disease Research 29/01/2019 William New The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) today announced the launch of the "Pandemic Response Box", which offers researchers free access to 400 compounds that could lead to development of new treatments for pandemic diseases. In return, researchers "will be expected to share data resulting from research on the molecules from the box in the public domain within 2 years of its generation." Continue reading -> G-Finder: R&D Investments Reach 10-Year Peak 23/01/2019 Health Policy Watch Funding for neglected disease research and development reached its highest level in a decade, with US $3.56 billion in investments in 2017. Continue reading -> Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Video: Stopping Malaria Relapse – New Approaches For An Old Disease 22/01/2019 Editorial team Medicines for Malaria Venture (MMV) tells the story of the new single-dose tefanoquine treatment for relapsing malaria, caused by the Plasmodium vivax species of the parasite – the most widespread in the world. Continue reading -> Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> Enter The African Medicines Agency, Continent’s First Super-Regulator? 03/07/2017 Tatum Anderson An African medicines agency, the continent’s first super-regulator, could be approved as soon as next year. Continue reading -> Posts navigation Newer posts
Ending TB: Multi-Sectoral Collaboration Needed To Tackle Disease Of Poverty, Board Says 01/02/2019 Editorial team There is a need to strengthen multisectoral collaboration to halt the global tuberculosis epidemic, WHO Executive Board (EB) members said in a review of the WHO End TB Strategy, which aims to reduce TB deaths by 90 percent by 2030. Continue reading -> DNDi, MMV Make 400 Compounds Available To Boost Pandemic Disease Research 29/01/2019 William New The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) today announced the launch of the "Pandemic Response Box", which offers researchers free access to 400 compounds that could lead to development of new treatments for pandemic diseases. In return, researchers "will be expected to share data resulting from research on the molecules from the box in the public domain within 2 years of its generation." Continue reading -> G-Finder: R&D Investments Reach 10-Year Peak 23/01/2019 Health Policy Watch Funding for neglected disease research and development reached its highest level in a decade, with US $3.56 billion in investments in 2017. Continue reading -> Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Video: Stopping Malaria Relapse – New Approaches For An Old Disease 22/01/2019 Editorial team Medicines for Malaria Venture (MMV) tells the story of the new single-dose tefanoquine treatment for relapsing malaria, caused by the Plasmodium vivax species of the parasite – the most widespread in the world. Continue reading -> Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> Enter The African Medicines Agency, Continent’s First Super-Regulator? 03/07/2017 Tatum Anderson An African medicines agency, the continent’s first super-regulator, could be approved as soon as next year. Continue reading -> Posts navigation Newer posts
DNDi, MMV Make 400 Compounds Available To Boost Pandemic Disease Research 29/01/2019 William New The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) today announced the launch of the "Pandemic Response Box", which offers researchers free access to 400 compounds that could lead to development of new treatments for pandemic diseases. In return, researchers "will be expected to share data resulting from research on the molecules from the box in the public domain within 2 years of its generation." Continue reading -> G-Finder: R&D Investments Reach 10-Year Peak 23/01/2019 Health Policy Watch Funding for neglected disease research and development reached its highest level in a decade, with US $3.56 billion in investments in 2017. Continue reading -> Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Video: Stopping Malaria Relapse – New Approaches For An Old Disease 22/01/2019 Editorial team Medicines for Malaria Venture (MMV) tells the story of the new single-dose tefanoquine treatment for relapsing malaria, caused by the Plasmodium vivax species of the parasite – the most widespread in the world. Continue reading -> Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> Enter The African Medicines Agency, Continent’s First Super-Regulator? 03/07/2017 Tatum Anderson An African medicines agency, the continent’s first super-regulator, could be approved as soon as next year. Continue reading -> Posts navigation Newer posts
G-Finder: R&D Investments Reach 10-Year Peak 23/01/2019 Health Policy Watch Funding for neglected disease research and development reached its highest level in a decade, with US $3.56 billion in investments in 2017. Continue reading -> Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Video: Stopping Malaria Relapse – New Approaches For An Old Disease 22/01/2019 Editorial team Medicines for Malaria Venture (MMV) tells the story of the new single-dose tefanoquine treatment for relapsing malaria, caused by the Plasmodium vivax species of the parasite – the most widespread in the world. Continue reading -> Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> Enter The African Medicines Agency, Continent’s First Super-Regulator? 03/07/2017 Tatum Anderson An African medicines agency, the continent’s first super-regulator, could be approved as soon as next year. Continue reading -> Posts navigation Newer posts
Tafenoquine – Milestone In Journey Towards Malaria Elimination 23/01/2019 Elaine Ruth Fletcher Tafenoquine, the first new drug to be developed in over 60 years to treat relapsing malaria, has in fact been around since the late 1970s, when researchers with the US Walter Reed Army Institute of Research first took note of its antimalarial properties. But the drug’s potential to cure relapsing malaria caused by the Plasmodium vivax parasite, the less deadly but most widespread malaria species, has only been recently been recognised. Continue reading -> Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Video: Stopping Malaria Relapse – New Approaches For An Old Disease 22/01/2019 Editorial team Medicines for Malaria Venture (MMV) tells the story of the new single-dose tefanoquine treatment for relapsing malaria, caused by the Plasmodium vivax species of the parasite – the most widespread in the world. Continue reading -> Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> Enter The African Medicines Agency, Continent’s First Super-Regulator? 03/07/2017 Tatum Anderson An African medicines agency, the continent’s first super-regulator, could be approved as soon as next year. Continue reading -> Posts navigation Newer posts
Amazonian Quest For P Vivax Malaria Solutions 23/01/2019 Elaine Ruth Fletcher Alejandro Llanos-Cuentas has been fighting P vivax malaria in Peru throughout most of his professional life. For many years, he failed to see significant inroads in control of the disease, which is most prevalent in the remote communities of the country’s Amazon region. Continue reading -> Video: Stopping Malaria Relapse – New Approaches For An Old Disease 22/01/2019 Editorial team Medicines for Malaria Venture (MMV) tells the story of the new single-dose tefanoquine treatment for relapsing malaria, caused by the Plasmodium vivax species of the parasite – the most widespread in the world. Continue reading -> Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> Enter The African Medicines Agency, Continent’s First Super-Regulator? 03/07/2017 Tatum Anderson An African medicines agency, the continent’s first super-regulator, could be approved as soon as next year. Continue reading -> Posts navigation Newer posts
Video: Stopping Malaria Relapse – New Approaches For An Old Disease 22/01/2019 Editorial team Medicines for Malaria Venture (MMV) tells the story of the new single-dose tefanoquine treatment for relapsing malaria, caused by the Plasmodium vivax species of the parasite – the most widespread in the world. Continue reading -> Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> Enter The African Medicines Agency, Continent’s First Super-Regulator? 03/07/2017 Tatum Anderson An African medicines agency, the continent’s first super-regulator, could be approved as soon as next year. Continue reading -> Posts navigation Newer posts
Single Dose Drug Effective For Recurrent Malaria, Trial Results Show 17/01/2019 Editorial team A powerful new single-dose anti-malarial drug can significantly lower the risk of recurrent malaria from the Plasmodium vivax (P. vivax) species of the parasite, according to clinical trial results published today in the New England Journal of Medicine (NEJM). Continue reading -> Enter The African Medicines Agency, Continent’s First Super-Regulator? 03/07/2017 Tatum Anderson An African medicines agency, the continent’s first super-regulator, could be approved as soon as next year. Continue reading -> Posts navigation Newer posts
Enter The African Medicines Agency, Continent’s First Super-Regulator? 03/07/2017 Tatum Anderson An African medicines agency, the continent’s first super-regulator, could be approved as soon as next year. Continue reading -> Posts navigation Newer posts